{"id":21735,"date":"2026-04-29T03:31:24","date_gmt":"2026-04-29T03:31:24","guid":{"rendered":"https:\/\/cinematicuniversal.com\/?p=21735"},"modified":"2026-04-29T03:32:51","modified_gmt":"2026-04-29T03:32:51","slug":"sanofi-consumer-healthcare-india-limited-reportsq126-revenue-at-%e2%82%b92292-mn-net-profit-at-%e2%82%b9678-mn","status":"publish","type":"post","link":"https:\/\/cinematicuniversal.com\/?p=21735","title":{"rendered":"Sanofi Consumer Healthcare India Limited reportsQ1\u201926 Revenue at \u20b92,292 MN, Net Profit at \u20b9678 MN!"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p>Sanofi Consumer Healthcare India Limited reports<br \/>\nQ1\u201926 Revenue at \u20b92,292 MN, Net Profit at \u20b9678 MN<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-21736\" src=\"https:\/\/cinematicuniversal.com\/wp-content\/uploads\/2026\/04\/sanof-300x82.jpg\" alt=\"\" width=\"300\" height=\"82\" srcset=\"https:\/\/cinematicuniversal.com\/wp-content\/uploads\/2026\/04\/sanof-300x82.jpg 300w, https:\/\/cinematicuniversal.com\/wp-content\/uploads\/2026\/04\/sanof.jpg 336w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Highlights for the Quarter Y-O-Y:<br \/>\n\u2022 Revenue at \u20b92,292 million, a growth of 33%<br \/>\n\u2022 Domestic Sales grew by 15.5%; aided by relaunches<br \/>\n\u2022 Export Sales grew by 144% due to low base<br \/>\n\u2022 Profit After Tax was up by 36%<\/p>\n<p>Chennai: Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) releases its financial results for the first quarter, demonstrating sustained growth momentum across key business segments. Revenue growth for the quarter stood at 33% year-on-year. Domestic sales grew by 15.5% aided by the relaunch of recalled products to the market. Profit after tax (PAT) for Q1 \u201826 reached \u20b9678 million, an increase of 36% on a year-on-year basis.<\/p>\n<p>Commenting on the Q1\u201926 results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said, \u201cOur performance this quarter reflects consistent, disciplined execution across our key markets. Domestic business outpaced the market, delivering both market share gains and volume growth, while exports made a meaningful contribution to overall results. Guided by science and driven by purpose, we remain committed to simplifying self\u2011care and making it more accessible and effective for consumers\u201d<\/p>\n<p>About Sanofi Consumer Healthcare India Limited.<br \/>\nSanofi Consumer Healthcare India Limited (SCHIL) emerged as a distinct legal entity following its demerger from Sanofi India Limited on 1st June 2024. SCHIL now operates independently, with a dedicated focus on the Consumer Healthcare sector.<br \/>\nWith an agile business model and strong brands, SCHIL is one of the leading players in India&#8217;s consumer healthcare market. Leveraging its global experience in consumer healthcare, SCHIL aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care and Multivitamins. SCHIL\u2019s key brands include Allegra\u00ae, DePURA\u00ae, Avil\u00ae and Combiflam\u00ae. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Sanofi Consumer Healthcare India Limited reports Q1\u201926 Revenue at \u20b92,292 MN, Net Profit at \u20b9678 MN Highlights for the Quarter Y-O-Y: \u2022 Revenue at \u20b92,292 million, a growth of 33% \u2022 Domestic Sales grew by 15.5%; aided by relaunches \u2022 Export Sales grew by 144% due to low base \u2022 Profit After Tax was [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":21736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[207],"tags":[],"class_list":["post-21735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=\/wp\/v2\/posts\/21735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21735"}],"version-history":[{"count":1,"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=\/wp\/v2\/posts\/21735\/revisions"}],"predecessor-version":[{"id":21737,"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=\/wp\/v2\/posts\/21735\/revisions\/21737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=\/wp\/v2\/media\/21736"}],"wp:attachment":[{"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cinematicuniversal.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}